JP2022540678A5 - - Google Patents
Info
- Publication number
- JP2022540678A5 JP2022540678A5 JP2022502486A JP2022502486A JP2022540678A5 JP 2022540678 A5 JP2022540678 A5 JP 2022540678A5 JP 2022502486 A JP2022502486 A JP 2022502486A JP 2022502486 A JP2022502486 A JP 2022502486A JP 2022540678 A5 JP2022540678 A5 JP 2022540678A5
- Authority
- JP
- Japan
- Prior art keywords
- polymorph
- degrees
- composition according
- diffraction pattern
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025113468A JP2025148397A (ja) | 2019-07-16 | 2025-07-04 | （ｒ）－４－（１－（（３－（ジフルオロメチル）－１－メチル－１ｈ－ピラゾール－４－イル）スルホニル）－１－フルオロエチル）－ｎ－（イソキサゾール－３－イル）ピペリジン－１－カルボキシアミドの多形体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874855P | 2019-07-16 | 2019-07-16 | |
| US62/874,855 | 2019-07-16 | ||
| PCT/US2020/042028 WO2021011586A1 (en) | 2019-07-16 | 2020-07-15 | Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113468A Division JP2025148397A (ja) | 2019-07-16 | 2025-07-04 | （ｒ）－４－（１－（（３－（ジフルオロメチル）－１－メチル－１ｈ－ピラゾール－４－イル）スルホニル）－１－フルオロエチル）－ｎ－（イソキサゾール－３－イル）ピペリジン－１－カルボキシアミドの多形体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022540678A JP2022540678A (ja) | 2022-09-16 |
| JP2022540678A5 true JP2022540678A5 (https=) | 2023-08-02 |
Family
ID=71895284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502486A Pending JP2022540678A (ja) | 2019-07-16 | 2020-07-15 | （ｒ）－４－（１－（（３－（ジフルオロメチル）－１－メチル－１ｈ－ピラゾール－４－イル）スルホニル）－１－フルオロエチル）－ｎ－（イソキサゾール－３－イル）ピペリジン－１－カルボキシアミドの多形体 |
| JP2025113468A Pending JP2025148397A (ja) | 2019-07-16 | 2025-07-04 | （ｒ）－４－（１－（（３－（ジフルオロメチル）－１－メチル－１ｈ－ピラゾール－４－イル）スルホニル）－１－フルオロエチル）－ｎ－（イソキサゾール－３－イル）ピペリジン－１－カルボキシアミドの多形体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113468A Pending JP2025148397A (ja) | 2019-07-16 | 2025-07-04 | （ｒ）－４－（１－（（３－（ジフルオロメチル）－１－メチル－１ｈ－ピラゾール－４－イル）スルホニル）－１－フルオロエチル）－ｎ－（イソキサゾール－３－イル）ピペリジン－１－カルボキシアミドの多形体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210053939A1 (https=) |
| EP (1) | EP3999504A1 (https=) |
| JP (2) | JP2022540678A (https=) |
| KR (1) | KR20220035176A (https=) |
| CN (1) | CN114127061A (https=) |
| AU (1) | AU2020315605A1 (https=) |
| BR (1) | BR112022000474A2 (https=) |
| CA (1) | CA3143965A1 (https=) |
| CL (1) | CL2022000050A1 (https=) |
| CO (1) | CO2022000117A2 (https=) |
| IL (1) | IL289817A (https=) |
| MX (1) | MX2022000606A (https=) |
| PE (1) | PE20220645A1 (https=) |
| WO (1) | WO2021011586A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116082326B (zh) * | 2022-12-16 | 2024-12-27 | 药康众拓(江苏)医药科技有限公司北京分公司 | 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途 |
| CN117865941B (zh) * | 2024-03-13 | 2024-06-28 | 上海方予健康医药科技有限公司 | 取代哌啶化合物及其制备方法和应用 |
| WO2025244956A1 (en) | 2024-05-20 | 2025-11-27 | MyoKardia, Inc. | Methods of manufacturing danicamtiv |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| US20050250789A1 (en) | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
| ES2522579T3 (es) | 2004-06-17 | 2014-11-17 | Cytokinetics, Inc. | Compuestos, composiciones y métodos |
| NZ590148A (en) | 2004-12-30 | 2012-04-27 | Janssen Pharmaceutica Nv | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| EP1866285A1 (en) | 2005-03-03 | 2007-12-19 | F. Hoffmann-Roche AG | 1-sulfonyl-piperdine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus |
| WO2008120759A1 (ja) | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | ウレア化合物およびその用途 |
| RU2462454C2 (ru) | 2007-06-20 | 2012-09-27 | Мицубиси Танабе Фарма Корпорейшн | Новое сульфонамидное производное малоновой кислоты и его фармацевтическое применение |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| BRPI0817211A2 (pt) | 2007-09-20 | 2017-05-16 | Irm Llc | composto composições como moduladores da atividade de gpr119 |
| RU2010116821A (ru) | 2007-10-01 | 2011-11-10 | Ф.Хоффманн-Ля Аг (Ch) | N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr |
| RU2487127C2 (ru) | 2007-10-09 | 2013-07-10 | Ф.Хоффманн-Ля Рош Аг | Хиральные цис-имидазолины |
| NZ600238A (en) | 2008-06-19 | 2014-04-30 | Takeda Pharmaceutical | Heterocyclic compound and use thereof |
| US8324178B2 (en) | 2008-10-31 | 2012-12-04 | The Regents Of The University Of California | Method of treatment using alpha-1-adrenergic agonist compounds |
| WO2010113377A1 (ja) | 2009-04-01 | 2010-10-07 | パナソニック株式会社 | デジタル周波数／位相ロックドループ |
| TWI472331B (zh) | 2009-11-11 | 2015-02-11 | Sumitomo Dainippon Pharma Co Ltd | ８－氮雙環〔３‧２‧１〕辛烷－８－羧醯胺衍生物 |
| US9771357B2 (en) | 2013-07-09 | 2017-09-26 | Ono Pharmaceutical Co., Ltd. | ALXR agonist compound |
| KR102249564B1 (ko) | 2013-08-07 | 2021-05-07 | 메르크 파텐트 게엠베하 | 피페리딘 우레아 유도체 |
| ES2933350T3 (es) | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| EP4234017B1 (en) * | 2015-01-22 | 2026-04-15 | MyoKardia, Inc. | Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm) |
| KR20220009440A (ko) | 2019-05-19 | 2022-01-24 | 미요카디아, 인크. | 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료 |
-
2020
- 2020-07-15 CN CN202080051794.8A patent/CN114127061A/zh active Pending
- 2020-07-15 US US16/929,230 patent/US20210053939A1/en not_active Abandoned
- 2020-07-15 EP EP20750115.6A patent/EP3999504A1/en active Pending
- 2020-07-15 JP JP2022502486A patent/JP2022540678A/ja active Pending
- 2020-07-15 CA CA3143965A patent/CA3143965A1/en active Pending
- 2020-07-15 WO PCT/US2020/042028 patent/WO2021011586A1/en not_active Ceased
- 2020-07-15 MX MX2022000606A patent/MX2022000606A/es unknown
- 2020-07-15 KR KR1020227004725A patent/KR20220035176A/ko active Pending
- 2020-07-15 BR BR112022000474A patent/BR112022000474A2/pt unknown
- 2020-07-15 PE PE2022000049A patent/PE20220645A1/es unknown
- 2020-07-15 AU AU2020315605A patent/AU2020315605A1/en active Pending
-
2022
- 2022-01-10 CL CL2022000050A patent/CL2022000050A1/es unknown
- 2022-01-12 IL IL289817A patent/IL289817A/en unknown
- 2022-01-12 CO CONC2022/0000117A patent/CO2022000117A2/es unknown
- 2022-02-23 US US17/678,569 patent/US12459919B2/en active Active
-
2025
- 2025-07-04 JP JP2025113468A patent/JP2025148397A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5159788B2 (ja) | １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼン１／２水和物の結晶形 | |
| JP2022540678A5 (https=) | ||
| JP2022540668A5 (https=) | ||
| JP2025176008A5 (https=) | ||
| JP2023519891A5 (https=) | ||
| HRP20240713T1 (hr) | Polimorfi od (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden- 1-il)-1-metil-1h-pirazol-4-karboksamida | |
| JP2016106102A (ja) | （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 | |
| JP2025148397A5 (https=) | ||
| JP2014074067A (ja) | メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形 | |
| CN103539795A (zh) | 阿哌沙班的多晶型及其制备方法 | |
| HK1045155A1 (en) | A crystalline form of celecoxib | |
| JP2024095561A5 (https=) | ||
| JP2022523368A5 (https=) | ||
| JP5160219B2 (ja) | テルミサルタンの製造方法 | |
| JPS59108749A (ja) | ５−｛（ｒ）−１−ヒドロキシ−２−〔（ｒ）−（１−メチル−３−フエニルプロピル）アミノ〕エチル｝サルチルアミドまたはその薬理学的に許容される酸付加塩の製造方法 | |
| JP2024547113A5 (https=) | ||
| JP2023530785A5 (https=) | ||
| JP2022542803A5 (https=) | ||
| CN104098570A (zh) | 替卡格雷晶型及其制备方法和用途 | |
| JP2024518429A5 (https=) | ||
| JP2023530786A5 (https=) | ||
| TWI518072B (zh) | 塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式 | |
| CN107033094A (zh) | 一种药物共晶的晶型及其制备方法和组合物 | |
| CA3091642A1 (en) | Agents and methods for treating dysproliferative diseases | |
| EP2155698A1 (en) | Novel thermodynamically stable polymorphic form-l of letrozole |